

MAY 18 2006

**510(k) Summary**  
**Dimension® TACR Calibrator**

This summary of 510(k) safety and effectiveness information is submitted in accordance with the requirements of SMDA 1990 and 21 CFR §807.92.

The assigned 510(k) number is: K060503

**1. Manufacturer's Name, Address, Telephone, and Contact Person, Date of Preparation**

Manufacturer: Dade Behring Inc.  
P.O. Box 6101  
Newark, DE 19714

Contact Information: Dade Behring Inc.  
P.O. Box 6101  
Newark, DE 19714  
Attn: Yuk-Ting Lewis  
Tel: 302-631-7626

Date of Preparation: Feb. 20, 2006

**2. Device Name / Classification**

Dimension® TACR Calibrator / Class II

**3. Identification of the Predicate Device**

Abbott IMx® Tacrolimus II Calibrators, P970007  
(Note: Tacrolimus test systems have been reclassified into Class II since the predicate was approved.)

**4. Device Description**

The Dimension® TACR Calibrator is a stabilized human whole blood hemolysate product containing tacrolimus. The kit consists of two vials of each calibrator level 1-5. The target concentrations are approximately 0, 3, 6, 12, 32.5 ng/mL tacrolimus.

**5. Device Intended Use**

The Dimension® TACR Calibrator is an in vitro diagnostic product intended to be used to calibrate the Tacrolimus (TACR) method for the Dimension® clinical chemistry system.

**6. Medical device to which equivalence is claimed and comparison information**

The Dimension® TACR Calibrators are substantially equivalent in intended use and technological characteristics to the Abbott IMx® Tacrolimus II Calibrators. Both devices are calibrators intended for use as a reference in measuring tacrolimus with their respective assays. The Dimension® TACR Calibrators consist of 5 calibrator levels – 0, 3, 6, 12, 32.5 ng/mL tacrolimus – in whole whole blood hemolysate. The Abbott IMx® Tacrolimus II Calibrators consist of 6 calibrator levels – 0, 3, 6, 12, 20, and 30 ng/mL – in whole blood hemolysate.



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
2098 Gaither Road  
Rockville MD 20850

Ms. Yuk-Ting Lewis  
Regulatory Affairs & Compliance Manager  
Dade Behring, Inc.  
PO Box 6101, M/S 514  
Newark, DE 19714-6101

MAY 18 2006

Re: k060503  
Trade/Device Name: Dimension® TACR Calibrator  
Regulation Number: 21 CFR 862.3200  
Regulation Name: Clinical toxicology calibrator  
Regulatory Class: Class II  
Product Code: DLJ  
Dated: April 20, 2006  
Received: May 4, 2006

Dear Ms. Lewis:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).

Page 2 –

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240) 276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/industry/support/index.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Alberto Gutierrez", with a stylized flourish at the end.

Alberto Gutierrez, Ph.D.

Director

Division of Chemistry and Toxicology

Office of In Vitro Diagnostic Device

Evaluation and Safety

Center for Devices and

Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known): K060503

Device Name: **Dimension® TACR Calibrator**

### Indications For Use:

The Dimension® TACR Calibrator is an in vitro diagnostic product intended to be used to calibrate the Tacrolimus (TACR) method for the Dimension® clinical chemistry system.

Prescription Use   x    
(Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use             
(21 CFR 801)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

  
Division Sign-Off

Page 1 of 1

Office of In Vitro Diagnostic Device  
Evaluation and Safety

510(k) K060503